Syncom Formulations India Ltd
- Market cap
- ₹ 1,993 Cr.
- P/E
- 23.3x
- P/B
- 5x
- 52-week range
- 10.21 – 27.49
- ROE
- 20%
- ROCE
- 27%
- Dividend yield
- 0.5%
- Debt / equity
- 0
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Syncom Formulations (India) Limited is an India-based company that is engaged in the pharmaceutical business. The Company is engaged in the development, manufacturing & sale of pharmaceutical products and services& trading of commodities and renting of properties. The Company manufactures and markets more than 200 pharmaceutical formulation products in various dosage forms, like Tablets, Capsules, Liquids Orals, Liquid Vials and Ampoule Injections and Dry Vial injections, Dry Syrups, Ointments and Inhalers. The Company's domestic division product categories include Cratus Life Care, Cratus Evolve and Cratus Right Nutrition. Its products include Ciprofloxacin Tablets USP 250 mg, Ciprofloxacin Tablets USP 500 mg, Ciprofloxacin Tablets USP 750 mg, Cefazolin For Injection USP 1 gm, Cefotaxime For Injection USP 1 gm, Ceftriaxone for Injection USP 500 mg, Albendazole Oral Suspension USP 100mg, Cetirizine Oral Solution BP, Clotrimazole Cream USP, Compound Benzoic Acid Ointment BP, and others.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Syncom Formulations India Ltd against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)23.3 against a typical 34: cheaper than most peers (1st = cheapest).76th of 220
- Sales growth+6.8% against a typical +15.6% from a year earlier.125th of 197
- Profit growth+56.3% against a typical +18.9% from a year earlier.47th of 160
- Share price, 3 months+54.3% against a typical −0.5%.10th of 200
- Size₹ 1,993.1 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).71st of 199
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 11 Aug 2026 | Financial Results/Dividend/Other business matters | To consider and approve the financial results for the period ended Jun 30, 2026, dividend and other business matters |
| 22 May 2026 | Financial Results/Other business matters | To consider and approve the financial results for the period ended March 31, 2026 and other business matters |
| 12 Feb 2026 | Financial Results/Other business matters | To consider and approve the financial results for the period ended December 31, 2025 and other business matters |
| 12 Nov 2025 | Financial Results/Other business matters | To consider and approve the financial results for the period ended September 30, 2025 and other business matters |
| 8 Aug 2025 | Financial Results/Other business matters | To consider and approve the financial results for the period ended Jun 30, 2025 and other business matters |
| 19 May 2025 | Financial Results/Other business matters | To consider and approve the financial results for the period ended March 31, 2025 and other business matters |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 62 | 63 | 73 | 87 | 101 | 127 | 148 | 117 | 121 | 115 | 134 | 125 |
| Expenses | 56 | 57 | 64 | 76 | 90 | 112 | 131 | 101 | 103 | 93 | 113 | 99 |
| Operating Profit | 6 | 7 | 9 | 10 | 12 | 15 | 17 | 16 | 19 | 21 | 21 | 26 |
| OPM % | 10% | 11% | 12% | 12% | 12% | 11% | 12% | 14% | 15% | 18% | 16% | 21% |
| Other Income | 4 | 4 | 3 | 1 | 4 | 4 | 7 | 6 | 5 | 5 | 14 | 8 |
| Interest | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 |
| Profit before tax | 8 | 9 | 9 | 10 | 15 | 17 | 23 | 20 | 22 | 25 | 33 | 32 |
| Tax % | 24% | 25% | 27% | 24% | 25% | 24% | 24% | 22% | 25% | 25% | 25% | 23% |
| Net Profit | 6 | 6 | 7 | 8 | 11 | 13 | 18 | 16 | 17 | 19 | 25 | 25 |
| EPS in Rs | 0.07 | 0.07 | 0.07 | 0.08 | 0.12 | 0.14 | 0.19 | 0.17 | 0.18 | 0.2 | 0.26 | 0.26 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 10%
- 5 Years
- 15%
- 3 Years
- 30%
- TTM
- 0%
- 10 Years
- 22%
- 5 Years
- 21%
- 3 Years
- 56%
- TTM
- 49%
- 10 Years
- 19%
- 5 Years
- 22%
- 3 Years
- 22%
- TTM
- —
- 10 Years
- 13%
- 5 Years
- 13%
- 3 Years
- 15%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Syncom Formulations India Ltd | ₹ 20.38 | ₹ 1,993 Cr. | 23.3x | 5x | 20% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Ankit Kedarmal Bankda
- Whole Time Chairman of the Board
- Rahul Vijay Bankda
- Chief Financial Officer
- Vaishali Agrawal
- Compliance Officer, Company Secretary
- Vijay Shankarlal Bankda
- Managing Director, Executive Director
- Kedarmal Shankarlal Bankda
- Whole-Time Director
Prices are delayed and for information only. Nothing on this page is investment advice.